<DOC>
	<DOC>NCT00100984</DOC>
	<brief_summary>The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.</brief_summary>
	<brief_title>A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>CD4 cell count greater than 50 cells/mm^3 HIV1 RNA viral load greater than or equal to 5000 copies/mL Patients must be HIV treatment experienced Patients diagnosed with HIV1 infection Female patients must not be able to have children or must be under effective contraceptives Female patients who are pregnant Have taken enfuvirtide and/or T1249 before Have serious kidney problems Alcohol and/or drug abuse Have had an organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
</DOC>